Real‐Life Effectiveness After Switching to Avalglucosidase Alfa in Late‐Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study
European Journal of Neurology · 2026-07 · 33 (7)
DOI: 10.1111/ene.70680 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Neurology, online erschienen am 16.07.2026. Verfasst von Céline Tard und 24 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, University of Lille, Lille, France. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, alpha-Glucosidases, Enzyme Replacement Therapy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Amicus Therapeutics, Astellas Pharma Europe.
Abstract (Originalsprache)
Late‐onset Pompe disease (LOPD) is a progressive myopathy. Enzyme replacement therapy is effective, but long‐term outcomes vary. Avalglucosidase alfa, shown to be non‐inferior to alglucosidase alfa in a phase 3 trial, became available in France through compassionate use for patients with insufficient response to alglucosidase alfa.
Methods
Data from the French Pompe registry were analyzed for patients who switched to avalglucosidase alfa with at least 1 year of follow‐up. Respiratory function (forced vital capacity, FVC) and motor function evaluated with gait performance (Six‐Minute Walk Test, 6MWT) were assessed before the switch, and one and 2 years after. Individual changes were compared using paired‐sample tests.
Results
Forty‐seven adult patients were included. A stabilization of motor decline was observed: prior to switching, the 6MWT decreased by −27 m/year, whereas an improvement of +17 m/year was seen during the first year after the switch ( p = 0.001), followed by overall stability in the second year (−10 m/year, p = 0.280). Respiratory changes were not statistically significant: a decline of 60 mL/year before the switch versus 10 mL/year after 1 year ( p = 0.161), and 20 mL/year during the second year ( p = 0.346). Three patients died during follow‐up, with causes unrelated to the disease or treatment.
Discussion
Gait deterioration halted during the first year after transitioning to avalglucosidase, with sustained stabilization thereafter, while respiratory parameters showed minimal change. For patients experiencing significant walking decline under alglucosidase alfa therapy, switching to avalglucosidase alfa resulted in disease stabilization, beginning with mild improvement in the first year and a return to pre‐switch baseline thereafter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, University of Lille, Lille, France.
- Centre de Référence Des Maladies NeuroMusculaires Nord - Est - Ile-de-France, Filnemus, Garches, France.
- Centre Hospitalier Universitaire de Nice, Système Nerveux Périphérique and Muscle, Hôpital Pasteur 2, Université Côte D'azur, Nice, France.
- Neurology Department, APHP, Raymond Poincaré University Hospital, FHU PHENIX, Garches, France.
- Referral Centre for Neuromuscular Diseases, ENMG and Neuromuscular Disease Unit, Hopital Neurologique, Hospices Civils de Lyon, Lyon, France.
- Centre de Référence Des Maladies NeuroMusculaires PACA Réunion Rhône Alpes, Filnemus, Marseille, France.
ORCID-Profile: Céline Tard, Armelle Magot, Claire Lefeuvre, Marco Spinazzi, Dalil Hamroun, Shahram Attarian, Pascal Laforêt
Förderung
- Sanofi
- Amicus Therapeutics
- Astellas Pharma Europe
Zitieren
APA
Tard, C., Sacconi, S., Taouagh, N., Bouhour, F., Michaud, M., Beltran, S., Fournier, M., Demurger, F., Lagrange, E., Nollet, S., Noury, J. B., Magot, A., Cintas, P., Renard, D., Deibener-Kaminsky, J., Lefeuvre, C., Davion, J. B., Salort-Campana, E., Arrassi, A., …, & Laforêt, P. (2026). Real‐Life Effectiveness After Switching to Avalglucosidase Alfa in Late‐Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70680
Vancouver
Tard C, Sacconi S, Taouagh N, Bouhour F, Michaud M, Beltran S, et al. Real‐Life Effectiveness After Switching to Avalglucosidase Alfa in Late‐Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70680
BibTeX
@article{Tard2026,
author = {Tard, Céline and Sacconi, Sabrina and Taouagh, Nadjib and Bouhour, Françoise and Michaud, Maud and Beltran, Stephane and Fournier, Maxime and Demurger, Florence and Lagrange, Emmeline and Nollet, Sylvain and Noury, Jean-Baptiste and Magot, Armelle and Cintas, Pascal and Renard, Dimitri and Deibener-Kaminsky, Joëlle and Lefeuvre, Claire and Davion, Jean-Baptiste and Salort-Campana, Emmanuelle and Arrassi, Azzeddine and Spinazzi, Marco and Hamroun, Dalil and Chitimus, Diana and Pompe Study Group, Pompe Study Group and Attarian, Shahram and Laforêt, Pascal},
title = {Real‐Life Effectiveness After Switching to Avalglucosidase Alfa in Late‐Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {7},
doi = {10.1111/ene.70680}
}
EUVIMED